Author

Brett E. Skolnick 1

1 Receptos, a wholly owned subsidiary of Celgene,San Diego,United States of America

ENDOSCOPIC AND CLINICAL EFFICACY DEMONSTRATED WITH ORAL OZANIMOD IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Barrett G. Levesque, Brett E. Skolnick, Caiyan Li, Darryl Penenberg, Richard Aranda, Allan Olson

RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, PHASE 2 TRIAL ASSESSING EFFICACY AND SAFETY OF THE NOVEL ANTI-NKG2D MONOCLONAL ANTIBODY NNC0142-0002 IN CROHN’S DISEASE: INSIGHTS FROM AN EXPOSURE-RESPONSE ANALYSIS

Matthieu Allez, Robert Petryka, Brett E. Skolnick, Maria Wisniewska Jarosinska, Rune Overgaard

Item 1 - 2 / 2
1